AcuraStem is a near-to-clinic, patient-based, biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
The main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes.
learn about our work
Neurodegenerative Disease Areas
AcuraStem has received an Amyotrophic Lateral Sclerosis Research Pro-gram (ALSRP) Therapeutic Development Award from the Department of Defense, Congressionally Directed Medical Research Programs (CDMRP) totaling $1 million.
“We are excited to add our collaborator Dr. Robert Bowser to our advisory board. Bob is a worldwide leader in ALS biomarker development. His expertise will be critical as we look to validate key, CNS-specific, mechanistic biomarkers for our PIKFYVE programs,” said Sam Alworth, co-founder and chief executive officer of AcuraStem.
AcuraStem CEO to Present at Translational Solutions’ Virtual Investor and Innovator Conference on Accelerating Innovations and Investments in Rare and Orphan Diseases in Partnership with the Keiretsu Forum Canada and Episome
Sam Alworth, has been invited to present at Translational Solutions’ Virtual Investor...